Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in Guillain-Barré Syndrome
NCT05701189Phase 2Withdrawn
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of efgartigimod alfa in Guillain-Barré syndrome (GBS). Planned start Sep 2024; status: withdrawn.
02
Drugs
efgartigimod alfa
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT05701189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701189.